0A

Quidelortho CorpLSE Quidelortho Stock Report

Last reporting period 30 Jun, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

3.052

Middle

Exchange

XLON - London Stock Exchange

0A55.L Stock Analysis

0A

Uncovered

Quidelortho Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-20/100

Low score

Market cap $B

3.052

Dividend yield

Shares outstanding

66.506 B

QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California. The firm is engaged in the development and manufacturing of advanced technologies in diagnostic testing. Its capabilities include immunoassay and molecular testing, clinical chemistry and transfusion medicine. The Company’s business units include Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine. Its Labs business unit includes Virology, Specialty Products, Specialty Products, Immunodiagnostics, VITROS Platform, XT Platform, VITROS XT Platform, and VITROS Automation Solutions. Its Molecular Diagnostics business includes Lyra, Solana, and Savanna. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, D, ELVIRA, ELVIS, FastPoint, FreshCells, InflammaDry, Lyra, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Vision, Quidel, QuickVue, QuickVue+, QVue, ReadyCells, Savanna, Sofia, Solana, Thyretain, Triage, Virena, and Vitros.

View Section: Eyestock Rating